Written by: Bryan J. Brinda, PharmD
Download Here

This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib pharmacotherapy in patients with relapsed/refractory AML that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test. Optimal patient identification, dosing, and follow-up are essential to help patients benefit fully while taking this medication. Continue reading Gilteritinib (XOSPATA) for Relapsed/Refractory Acute Myeloid Leukemia (AML)

Read More